Victor Rusu

Victor Rusu is an Associate at Apple Tree Partners, a life sciences venture capital firm based in Boston, Massachusetts. In this capacity, he specializes in early-stage biotechnology investments, focusing primarily on sourcing and evaluating startups that are developing novel clinical therapeutics, diagnostics, and platform technologies. Since joining the investment team around 2020, Rusu has contributed to financial analysis and portfolio management for a fund that has backed prominent companies such as Obsidian Therapeutics, Asgard Therapeutics, and Kymab. His analytical work directly supports the firm's broader capital deployment strategy, which includes leading significant funding rounds like the $105 million Series B for Obsidian Therapeutics in late 2021. Rusu's current professional focus remains on identifying and scaling innovative biotechnology ventures that leverage institutional research from hubs like Harvard Medical School to advance the global life sciences sector.